『Hematologic Oncology Update』のカバーアート

Hematologic Oncology Update

Hematologic Oncology Update

著者： Dr. Neil Love
無料で聴く

今ならプレミアムプランが3カ月 月額99円

2026年5月12日まで。4か月目以降は月額1,500円で自動更新します。

概要

 Featuring one-on-one interviews conducted by Dr Neil Love, this series provides medical oncologists with access to an array of important perspectives and information on relevant advances in the treatment of hematologic cancer to facilitate optimal patient care.Copyright 2025 Research To Practice. All Rights Reserved 科学 衛生・健康的な生活 身体的病い・疾患
エピソード
  • CELMoDs for Multiple Myeloma — Microlearning Activity 2 with Dr Paul G Richardson

    CELMoDs for Multiple Myeloma — Microlearning Activity 2 with Dr Paul G Richardson
    2026/04/10

    Dr Paul G Richardson from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses how CELMoDs function, available data with these agents and their possible future role in the treatment of multiple myeloma.

    CME information and select publications here.
    続きを読む 一部表示
    25 分
  • Immune Thrombocytopenia — Microlearning Activity 4 with Dr Hanny Al-Samkari: ASH 2025 Review

    Immune Thrombocytopenia — Microlearning Activity 4 with Dr Hanny Al-Samkari: ASH 2025 Review
    2026/04/01

    Dr Hanny Al-Samkari from Massachusetts General Hospital in Boston discusses recent developments from the ASH 2025 Annual Meeting involving the use of Bruton tyrosine kinase inhibitors and BAFF-R antagonists in the treatment of immune thrombocytopenia.

    CME information and select publications here.
    続きを読む 一部表示
    25 分
  • CELMoDs for Multiple Myeloma — Microlearning Activity 1 with Dr Paul G Richardson

    CELMoDs for Multiple Myeloma — Microlearning Activity 1 with Dr Paul G Richardson
    2026/03/23

    Dr Paul G Richardson from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses how CELMoDs function, available data with these agents and their possible future role in the treatment of multiple myeloma.

    CME information and select publications here.
    続きを読む 一部表示
    24 分
まだレビューはありません